The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective

European Journal of Haematology

Volumn 85, Issue 6, 2010, Pages 484-491

  Hornberger, John ^a,b   Rickert, Joseph ^a   Dhawan, Ravinder ^c   Liwing, Johan ^d   Aschan, Johan ^d   Löthgren, Mikael ^d  

^a Cedar Associates LLC   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNSON AND JOHNSON   (United States)

^d Janssen Cilag   (Sweden)

Author keywords

Bortezomib; Cost effectiveness; Dexamethasone; Lenalidomide; Multiple myeloma

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; BONE PAIN; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG MEGADOSE; FATIGUE; FEMALE; HUMAN; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; STROKE; SWEDEN; SYNCOPE; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS, PHASE III AS TOPIC; COSTS AND COST ANALYSIS; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIPLE MYELOMA; PYRAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SURVIVAL RATE; SWEDEN; THALIDOMIDE;

EID: 78349278026     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01526.x     Document Type: Article

References (38)

1. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Björkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007;25:1993-9.
2. Kyle R, Therneau T, Rajkumar S, et al. Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. Cancer 2004;101:2667-74.
3. Multiple Myeloma Research Foundation. Multiple Myeloma Research Foundation. Newly diagnosed patients: What is multiple myeloma? cited January 19, 2009.
4. Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004;79:867-74.
5. Belch A, Shelley W, Bergsagel D, Wilson K, Klimo P, White D, Willan A. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988;57:94-9.
6. Barlogie B, Alexanian R. Therapy of primary resistant and relapsed multiple myeloma. Onkologie 1986;9:210-4.
7. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-60.
8. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42.
9. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32.
10. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147-52.
11. Gelber R. Comparing treatments using quality-adjusted survival: the Q-Twist method. Am Stat 1995;49:161-9.
12. Gelber R, Goldhirsch A, Cavalli F. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med 1991;114:621-8.
13. Sherrill B, Amonkar M, Stein S, et al. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer 2008;99:711-5.
14. Drummond M. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 1997.
15. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
16. Gulbrandsen N, Wisloff F, Brinch L, et al. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 2001;18:65-77.
17. Mujica-Mota R, Bagust A, Haycox A, et al. Mapping health-related quality of life (HRQOL) measurements into generic utility measures (EQ-5D): a case study with bortezomib (Velcade). Value Health 2004; 7: 683 (abst).
18. Nord E, Wisloff F, Hjorth M, et al. Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial. Pharmacoeconomics 1997;12:89-103.
19. Van Agthoven M, Segeren CM, Buijt I, Uyl-de Groot CA, Van Der Holt B, Lokhorst HM, Sonneveld P. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study. Eur J Cancer 2004;40:1159-69.
20. The Southern Regional Health Care Board. Prices and Reimbursements for the Southern Health Care Region 2006. Lund, Sweden. cited August 31, 2009.
21. The Swedish Institute for Health Economics. Technical report 2007-03-05 rev 2007-08-23. A report on resource utilization and costs for Swedish patients treated for multiple myeloma. 2007.
22. Millenium Pharmaceuticals I. Addendum to Final Clinical Study Report M341-CSR-003 VELCADE™ (bortezomib) for Injection submitted to US Food and Drug Administration (FDA) and to the European Agency for the Evaluation of Medicinal Products (EMEA). (Section 9.1, page 43). Aug 3, 2005.
23. FASS.se. Källan till kunskap om läkemedel 2009; cited February 19, 2009.
24. FASS. Läkemedel I Sverige V Läkemedelsinformation AB (Pharmaceutical Information) Stockholm, 2008, cited December 22, 2008.
25. The Pharmaceutical Benefits Board Decision: Revlimid application for inclusion in pharmaceutical reimbursement scheme (reference 2274/2007). Solna, Sweden; 2008.
26. LFNAR. General guidelines for economic evaluations from the Pharmaceutical Benefits Board; 2003.
27. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-31.
28. Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006;132:205-12.
29. Facon T, Mary JY, Pegourie B, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006;107:1292-8.
30. Oken MM, Harrington DP, Abramson N, et al. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Cancer 1997;79:1561-7.
31. Hernandez JM, Garcia-Sanz R, Golvano E, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 2004;127:159-64.
32. Ghatnekar O, Alvegård T, Andhult C, et al. Direct hospital resource utilization and costs of treating patients with multiple myeloma in South-West Sweden: a 5-year retrospective analysis. Clin Ther 2008;30:1710-3.
33. World Health Organization (WHO). Table: threshold values for intervention cost-effectiveness by region. 2009. cited February 19, 2009.
34. Persson U, Hjelmgren JH. och sjukvården behöver kunskap om hur befolkningen värderar hälsan. Läkartidningen 2003;100:3436-7.
35. Central Intelligence Agency. The World Fact book-Sweden. 2008 December 18; cited January 20, 2009.
36. Lakemedelsformansnamnden. (LFN) 1154/2006; 2007 February 20.
37. Lakemedelsformansnamnden. (LFN) 1154/2006; 2008 February 25.
38. Rajkumar SV, Blood E, Vesole D, Fonseca R, et al. Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-6.